A phase I study of rDNA alpha-2b interferon as a 6-week continuous intravenous infusion
- 13 Downloads
- 5 Citations
Summary
Sixteen patients with advanced malignancy were treated with rDNA alpha-2b interferon using a continuous 6-week i.v. schedule. Patients received 1 μg, 3 mg, 5 mu and 7 mu/m2/day via a portable infusion pump system, all therapy being on an outpatient basis. The dose-limiting toxicity occurring at 7 mg/m2/day was lethargy and somnolence. Five million units (mu) was the maximum tolerated dose but significant nausea, anorexia and lethargy affected 4/5 patients at this level. A dose of 3 mu/m2/day was well tolerated, producing little disturbance of normal activity in the majority of patients. Suppression of WBC and platelets was seen at all doses but was not dose-limiting. There was increasing severity of derangement of hepatic transaminases with increasing dose, and the occurrence of liver toxicity appeared to correlate with nausea, anorexia and lethargy.
Assay of serum interferon during the infusion showed that this system maintained a constant level of interferon in the blood. However, the increase did not show a linear pattern with increasing dose, suggesting saturation of metabolic inactivation at 7 mu/m2/day.
We recommend that a dose of 3 mu/m2/day be used in future studies of prolonged infusions of alpha-2 interferon.
Keywords
Interferon Intravenous Infusion Normal Activity Constant Level Infusion PumpPreview
Unable to display preview. Download preview PDF.
References
- 1.Adams F, Quesada JR, Gutterman JU (1984) Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. JAMA 252:938Google Scholar
- 2.Bornemann LD, Spiegel HE, Dziewanowska ZE, Krown SE, Colburn WA (1985) Intravenous and intramuscular pharmacokinetics of recombinant leukocyte A interferon. Eur J Clin Pharmacol 28:469Google Scholar
- 3.Chronic Leukemia-Myeloma Task Force, National Cancer Institute (1973) Proposed guidelines for protocol studies. II. Plasma cell myeloma. Cancer Chemother Rep 4:145Google Scholar
- 4.Cooper MR, Fefer A, Thompson J, Case DC, Kempf R, Neefe J, Bickers J, Scarffe JH, Spiegel R, Bonnem E (1982) Alpha-2 interferon/melphalan/prednisolone in previously untreated patients with multiple myeloma. Cancer Treat Rep 70:473Google Scholar
- 5.Edelstein MB, Schellekens H, Lauren T, Gauchi L (1983) A phase I clinical tolerance study of rDNA alpha-2 human interferon in patients with non-reticuloendothelial system malignancies. Eur J Cancer Clin Oncol 19:891Google Scholar
- 6.Ghezzi P, Bianchi M, Gianera L, Landolfo S, Salmona M (1985) Role of reactive oxygen intermediates in the interferon-mediated depression of hepatic drug metabolism and protective effect on N-acetylcystein in mice. Cancer Research 45:3444Google Scholar
- 7.Gresser I (1983) The antitumor effects of interferon in mice. In: Sikora K (ed) Interferon and cancer. Plenum, New York, pp 65–76Google Scholar
- 8.Mattson K, Niiranen A, Laaksonen D, Cantell K (1984) Psychometric monitoring of interferon neurotoxicity. Lancet 1:275Google Scholar
- 9.Nethersell A, Sikora K (1985) In: Papadimitriou J-T (ed) Interferons: their impact in biology and medicine. Oxford Medical Publications, Oxford, pp 133Google Scholar
- 10.Plasse T, Ohnuma T, Brukner H, Chamberlain K, Mass T, Holland JF (1982) Portable infusion pumps in ambulatory chemotherapy. Cancer 50:27Google Scholar
- 11.Quesada JR, Reuben J, Manning J et al. (1984) Alpha interferon for induction of remission in hairy cell leukaemia. N Engl J Med 310:15Google Scholar
- 12.Rohatiner AZS, Balkwill FR, Griffin DB, Malpas JS, Lister TA (1982) A phase I study of human lymphoblastoid interferon administered by continuous intravenous infusion. Cancer Chemother Pharmacol 9:97Google Scholar
- 13.Rohatiner AZS, Prior PF, Burton AC, Smith AT, Balkwill FR, Lister TA (1983) Central nervous system toxicity of interferon. Br J Cancer 47:419Google Scholar
- 14.Shah I, Band J, Samson M, Young J, Lerner AM (1983) Pharmacokinetics and tolerance of intravenous and intramuscular recombinant alpha-2 interferon in patients with malignancies. J Clin Research 31:696Google Scholar
- 15.Sherwin SA, Knost JA, Fein S, Abrams PG, Foon KA, Ochs JJ, Schoenberger C, Maluish AE, Oldham RK (1982) A multiple dose phase-I trial of recombinant leukocyte A interferon in cancer patients. JAMA 248:2461Google Scholar
- 16.Takeyama H, Kawashima K, Kobayashi M, Yamada K, Ito Y (1978) Antitumor effect of interferon preparations on murine transplantable tumors. Gann 69:641Google Scholar
- 17.Wagstaff J, Chadwick G, Howell A, Thatcher N, Scarffe JH, Crowther D (1984) A phase I toxicity study of human rDNA interferon in patients with solid tumours. Cancer Chemother Pharmacol 13:100Google Scholar
- 18.Wagstaff J, Loynds P, Crowther D (1986) A phase II study of rDNA alpha-2 interferon in patients with low grade non-Hodgkins lymphoma. Cancer Chemother Pharmacol 18:54Google Scholar
- 19.Willson J, Yordan E, Sielaff K, Tuttle R, Buchler D, Whisnarb S, Bordan E, Davies T (1984) High dose lymphoblastoid interferon (HLBI) administered as a 10 day continuous infusion in ovarian cancer: an ECOG pilot study. Clin Research 32:424Google Scholar